KYMR Smart Money
Kymera Therapeutics, Inc.
1W: +6.3%
1M: +2.6%
3M: +8.2%
YTD: +57.8%
1Y: +98.8%
3Y: +865.9%
5Y: +112.9%
$117.57
+2.73 (+2.38%)
After Hours: $113.62 (-3.94, -3.36%)
Weekly Expected Move ±5.5%
$99
$105
$111
$117
$123
Credit Risk of going bust: lower than 78% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.12 (down 99.9%), Kymera Therapeutics, Inc. would be worth roughly what it owes.
Total debt $82.2M against a stock market value of $9.45B.
Distance to default 9.26 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $41.1M (short-term plus half of long-term), stock volatility 57.7%; Altman Z'' 10.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026310
Institutions Holding
+16 vs prior
101.8%
Ownership
+27.16%
51
New
97
Increased
107
Reduced
23
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 262 | $116.12 | $30K | Filing |
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 8,230 | $115.40 | $950K | Filing |
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 7,601 | $114.43 | $870K | Filing |
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 4,876 | $113.24 | $552K | Filing |
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 5,506 | $112.42 | $619K | Filing |
| 2026-10-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 3,525 | $111.44 | $393K | Filing |
| 2026-09-04 | Adams Brian | officer: chief legal officer | S-Sale | 2,137 | $117.57 | $251K | Filing |
| 2026-09-04 | Adams Brian | officer: chief legal officer | S-Sale | 3,025 | $116.81 | $353K | Filing |
| 2026-09-04 | Adams Brian | officer: chief legal officer | S-Sale | 1,209 | $115.55 | $140K | Filing |
| 2026-07-27 | Rooney Terence | officer: chief medical officer | A-Grant/Award | 38,000 | $— | $0 | Filing |
| 2026-07-07 | Mainolfi Nello | officer: chief executive officer | S-Sale | 50,000 | $119.00 | $6.0M | Filing |
| 2026-07-07 | Mainolfi Nello | officer: chief executive officer | M-Option Exercise | 50,000 | $2.08 | $104K | Filing |
| 2026-07-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 3,336 | $116.56 | $389K | Filing |
| 2026-07-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 44,050 | $115.69 | $5.1M | Filing |
| 2026-07-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 24,105 | $114.96 | $2.8M | Filing |
| 2026-07-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 6,626 | $113.98 | $755K | Filing |
| 2026-07-01 | Mainolfi Nello | officer: chief executive officer | S-Sale | 1,883 | $112.80 | $212K | Filing |
| 2026-07-01 | Goodman Noah | officer: chief business officer | S-Sale | 3,389 | $114.29 | $387K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 4,110 | $114.19 | $469K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 3,200 | $117.70 | $377K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 6,153 | $116.99 | $720K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 7,971 | $115.82 | $923K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 51,375 | $114.77 | $5.9M | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 1,100 | $112.79 | $124K | Filing |
| 2026-06-30 | Jacobs Bruce N. | officer: chief financial officer | S-Sale | 1,700 | $111.57 | $190K | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| FMR LLC | 12,349,256 | $1.4B | +649,306 | 2026-06-30 | Filing |
| BAKER BROS. ADVISORS LP | 8,657,242 | $993M | — | 2026-06-30 | Filing |
| Avoro Capital Advisors LLC | 7,474,747 | $857M | — | 2026-06-30 | Filing |
| BlackRock, Inc. | 5,538,210 | $635M | +477,334 | 2026-06-30 | Filing |
| BVF INC/IL | 3,872,052 | $444M | -1,630,658 | 2026-06-30 | Filing |
| WELLINGTON MANAGEMENT GROUP LLP | 3,675,028 | $421M | -214,659 | 2026-06-30 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,992,193 | $343M | +118,137 | 2026-06-30 | Filing |
| Siren, L.L.C. | 2,935,830 | $337M | -251,000 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,932,378 | $336M | +52,054 | 2026-06-30 | Filing |
| Atlas Venture Life Science Advisors, LLC | 2,847,541 | $327M | -1,730,467 | 2026-06-30 | Filing |
| STATE STREET CORP | 2,737,226 | $314M | +347,459 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 1,816,331 | $208M | +170,981 | 2026-06-30 | Filing |
| Capital Research Global Investors | 1,388,881 | $159M | -284,394 | 2026-06-30 | Filing |
| GOLDMAN SACHS GROUP INC | 1,187,333 | $136M | +298,924 | 2026-06-30 | Filing |
| UBS Group AG | 1,007,777 | $116M | -16,075 | 2026-06-30 | Filing |
| Driehaus Capital Management LLC | 919,233 | $105M | -124,350 | 2026-06-30 | Filing |
| Merck & Co., Inc. | 772,165 | $89M | — | 2026-06-30 | Filing |
| NORGES BANK | 757,246 | $87M | +757,246 | 2026-06-30 | Filing |
| FEDERATED HERMES, INC. | 749,398 | $86M | +212,718 | 2026-06-30 | Filing |
| DIMENSIONAL FUND ADVISORS LP | 745,152 | $85M | +152,273 | 2026-06-30 | Filing |